Rani Therapeutics (NASDAQ:RANI - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The firm had revenue of $1.03 million during the quarter. On average, analysts expect Rani Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Rani Therapeutics Price Performance
NASDAQ:RANI opened at $1.12 on Monday. The company has a market cap of $64.38 million, a P/E ratio of -1.06 and a beta of 0.24. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. The firm's fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.67. Rani Therapeutics has a one year low of $1.02 and a one year high of $7.88.
Analyst Ratings Changes
RANI has been the subject of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Rani Therapeutics in a report on Thursday, April 3rd. Canaccord Genuity Group reiterated a "buy" rating and set a $9.00 price objective on shares of Rani Therapeutics in a research note on Wednesday, February 26th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $12.33.
Get Our Latest Stock Report on RANI
About Rani Therapeutics
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
